Clinical trials: Relapsed
Relapsed Acute Myeloid Leukemia
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient…
- Trial name
- NCT04582864
- Testing
- Flotetuzumab, Donor lymphocyte infusion
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)
The purpose of this study is to characterize the multiple myeloma (MM) participants with symptomatic relapse and/or refractory disease in Spain.
- Trial name
- NCT03188536
- Testing
- No Intervention
- Where
- 30 sites in Spain
- Volunteers
- 282 people
- Sponsor
- Takeda
Carcinoma, Renal Cell
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have…
- Trial name
- CheckMate 914 (NCT03138512)
- Testing
- nivolumab, ipilimumab
- Where
- 200 sites in United States, Argentina and 23 more
- Volunteers
- 1,641 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
This phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab, and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating patients with relapsed B-cell non-Hodgkin…
- Trial name
- NCT00695409
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome.
- Trial name
- NCT02848001
- Testing
- CC-90009
- Where
- 20 sites in United States, Canada and 4 more
- Volunteers
- 101 people
- Sponsor
- Celgene
Relapsed Chronic Lymphocytic Leukemia
A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication. More recently metformin has been shown to act against carcinomas by two mechanisms: 1) an indirect, insulin-dependent mechanism…
- Trial name
- NCT01750567
- Testing
- Metformin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma.
- Trial name
- NCT01348919
- Testing
- CEP-18770, Lenalidomide, Dexamethasone
- Where
- 8 sites in United States, New Zealand
- Volunteers
- 11 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)
ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
This is a multicenter, single-arm study for safety and efficacy.
- Trial name
- NCT01055067
- Testing
- Tivantinib (ARQ 197)
- Where
- 10 sites in United States, France and 1 more
- Volunteers
- 27 people
- Sponsor
- Daiichi Sankyo
Tumors
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.
- Trial name
- NCT00339144
- Testing
- Dasatinib
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine for the treatment of patients with relapsed…
- Trial name
- NCT02594163
- Testing
- Brentuximab Vedotin, Rituximab, Bendamustine
- Where
- 50 sites in United States, Czechia and 5 more
- Volunteers
- 25 people
- Sponsor
- Seagen Inc.
Estrogen Receptor Positive, Postmenopausal
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor (ER) positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned (come back) after a…
- Conditions
- Estrogen Receptor Positive, Postmenopausal, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02657928
- Testing
- Laboratory Biomarker Analysis, Letrozole, Ribociclib
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Ulcerative Colitis
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
The study hypothesis is that withdrawal of carrageenan will lead to a longer, relapse free interval in patients with ulcerative colitis.
- Trial name
- NCT01065571
- Testing
- carrageenan, dietary intervention with no-carrageenan diet
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Illinois Chicago
Relapsed Acute Leukemia, Refractory Acute Leukemia
A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
1.1 Primary Objectives To determine the feasibility, tolerability, and toxicities of administering the selective CDK 4/6 inhibitor PD 0332991 prior to the combination of ara-C and Mitoxantrone for adults with relapsed and…
- Conditions
- Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia
- Trial name
- NCT01701375
- Testing
- PD 0332991
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)
- Trial name
- NCT04930536
- Testing
- Acalabrutinib capsule
- Where
- 15 sites in India
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
- Trial name
- NCT02717611
- Testing
- ACP-196 (acalabrutinib)
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Acerta Pharma BV
Acute Leukemia, Acute Myeloid Leukemia
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT02722668
- Testing
- Fludarabine, Cyclophosphamide, MMF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
This is a two-cohort, multicenter, open-label study of tafasitamab (MOR208) combined with idelalisib or venetoclax in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- COSMOS (NCT02639910)
- Testing
- Tafasitamab, Idelalisib, Venetoclax
- Where
- 17 sites in United States, Austria and 4 more
- Volunteers
- 24 people
- Sponsor
- MorphoSys AG
Multiple Sclerosis
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)
To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)
- Trial name
- NCT00537082
- Testing
- FTY720
- Where
- 18 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Novartis
Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse
CT-011 MAb in DLBCL Patients Following ASCT
Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL) following relapse of the disease.
- Conditions
- Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT00532259
- Testing
- CT-011
- Where
- 27 sites in United States, India and 1 more
- Volunteers
- 72 people
- Sponsor
- CureTech Ltd
Multiple Sclerosis
Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
The primary objective of the study is to compare the immunogenicity of the new fetal bovine serum (FBS)-free/human serum albumin (HSA)-free Rebif® formulation (RNF) to historical data.
- Trial name
- RNF (NCT00110396)
- Testing
- Interferon-beta-1a FBS-free/HSA-free
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- EMD Serono
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.